Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor

被引：0
|
作者：
William B. Smith
Jesse Hall
Jolene K. Berg
Michal Kazimir
Amy Yamamoto
Susan Walker
Caroline A. Lee
Zancong Shen
David M. Wilson
Dongmei Zhou
Michael Gillen
Thomas C. Marbury
机构：
[1] University of TN Medical Center,Volunteer Research Group
[2] Ardea Biosciences,undefined
[3] Inc,undefined
[4] DaVita Clinical Research,undefined
[5] DaVita Clinical Research,undefined
[6] AstraZeneca Pharmaceuticals LP,undefined
[7] Orlando Clinical Research Center,undefined
来源：
Clinical Drug Investigation | 2018年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：703 / 713
页数：10
相关论文
共 50 条
  • [21] Enoxaparin pharmacokinetics and pharmacodynamics in renal impairment
    Sanderink, GJ
    Guimart, C
    Jariwala, N
    Shukla, U
    Ozoux, ML
    Boutouyrie, B
    Hutman, HW
    Gutierrez, M
    Marbury, T
    Preston, R
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) : 229A - 229A
  • [22] The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor
    Kielbasa, William
    Tesfaye, Eshetu
    Luffer-Atlas, Debra
    Mitchell, Malcolm I.
    Turik, Michael A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (12) : 2011 - 2019
  • [23] The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor
    William Kielbasa
    Eshetu Tesfaye
    Debra Luffer-Atlas
    Malcolm I. Mitchell
    Michael A. Turik
    European Journal of Clinical Pharmacology, 2013, 69 : 2011 - 2019
  • [24] THE PHARMACOKINETICS AND PHARMACODYNAMICS OF QUINAPRIL AND QUINAPRILAT IN RENAL IMPAIRMENT
    BEGG, EJ
    ROBSON, RA
    BAILEY, RR
    LYNN, KL
    FRANK, GJ
    OLSON, SC
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (02) : 213 - 220
  • [25] THE PHARMACOKINETICS AND PHARMACODYNAMICS OF NICARDIPINE IN PATIENTS WITH RENAL IMPAIRMENT
    AHMED, JH
    ELLIOTT, HL
    GRANT, AC
    RODGER, RSC
    REID, JL
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (01) : P145 - P146
  • [26] Pharmacokinetics and pharmacodynamics of evolocumab in patients with renal impairment
    Lee, E.
    Gibbs, J.
    Wasserman, S. M.
    Block, G.
    Emery, M. G.
    Abosaleem, B.
    Tracy, M.
    Gibbs, M.
    Somaratne, R.
    Kasichayanula, S.
    Hanafin, P.
    Egbuna, O.
    EUROPEAN HEART JOURNAL, 2016, 37 : 343 - 343
  • [27] Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian
    Brase, Christine
    Schmitz, Sebastian
    Sommer, Katharina
    Halabi, Atef
    Kanefendt, Friederike
    CLINICAL PHARMACOKINETICS, 2024, 63 (11) : 1631 - 1648
  • [28] Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor
    Hu, Xiaotong
    Lin, Hongda
    Huang, Yan
    Xu, Pingsheng
    Xu, Bin
    Yu, Haibin
    Wang, Meixia
    Feng, Sheng
    Li, Yijing
    Shen, Kai
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (12): : 1576 - 1585
  • [29] Effect of renal function on the pharmacokinetics and pharmacodynamics of argatroban (a direct thrombin inhibitor).
    Hurstling, MJ
    Joffrion, JL
    Brooks, RL
    Swan, SK
    Sarris, AH
    BLOOD, 1996, 88 (10) : 658 - 658
  • [30] Effect of renal impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX-67), a novel non-purine selective inhibitor of xanthine oxidase.
    Swan, S
    Khosravan, R
    Mayer, MD
    Wu, JT
    Pa, WA
    MacDonald, PA
    Vernillet, L
    Joseph-Ridge, N
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S529 - S529
12345